735 related articles for article (PubMed ID: 8093229)
1. Autoreactive and heat shock protein 60-recognizing CD4+ T-cells show antitumor activity against syngeneic fibrosarcoma.
Harada M; Matsuzaki G; Yoshikai Y; Kobayashi N; Kurosawa S; Takimoto H; Nomoto K
Cancer Res; 1993 Jan; 53(1):106-11. PubMed ID: 8093229
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.
Eto M; Harada M; Tatsugami K; Harano M; Koga H; Matsuzaki G; Naito S
BJU Int; 2005 Feb; 95(3):421-4. PubMed ID: 15679807
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. I. Destruction of B16 melanoma cells mediated by bystander cytolysis in vitro.
Shiohara T; Ruddle NH; Horowitz M; Moellmann GE; Lerner AB
J Immunol; 1987 Mar; 138(6):1971-8. PubMed ID: 3102609
[TBL] [Abstract][Full Text] [Related]
4. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
Tsujino M
Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
[TBL] [Abstract][Full Text] [Related]
5. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
6. Induction of antigen-specific CD4+ HLA-DR-restricted cytotoxic T lymphocytes as well as nonspecific nonrestricted killer cells by the recombinant mycobacterial 65-kDa heat-shock protein.
Ab BK; Kiessling R; Van Embden JD; Thole JE; Kumararatne DS; Pisa P; Wondimu A; Ottenhoff TH
Eur J Immunol; 1990 Feb; 20(2):369-77. PubMed ID: 1690136
[TBL] [Abstract][Full Text] [Related]
7. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
[TBL] [Abstract][Full Text] [Related]
8. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC.
Sugihara S; Fujiwara H; Niimi H; Shearer GM
J Immunol; 1995 Aug; 155(3):1619-28. PubMed ID: 7543527
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
10. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
11. Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Abrams SI; Dobrzanski MJ; Wells DT; Stanziale SF; Zaremba S; Masuelli L; Kantor JA; Schlom J; Masuelle L [corrected to Masuelli L]
Eur J Immunol; 1995 Sep; 25(9):2588-97. PubMed ID: 7589131
[TBL] [Abstract][Full Text] [Related]
12. A tumor-specific Th2 clone initiating tumor rejection via primed CD8+ cytotoxic T-lymphocyte activation in mice.
Shen Y; Fujimoto S
Cancer Res; 1996 Nov; 56(21):5005-11. PubMed ID: 8895757
[TBL] [Abstract][Full Text] [Related]
13. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice.
Hashemi SM; Hassan ZM; Soudi S; Ghazanfari T; Kheirandish M; Shahabi S
Int Immunopharmacol; 2007 Jul; 7(7):920-7. PubMed ID: 17499194
[TBL] [Abstract][Full Text] [Related]
15. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
16. Establishment of three PPD-reactive helper T cell clones with distinct functions in B cell activation.
Sano Y; Yamada G; Dobashi K; Mizuochi T; Hamaoka T; Takatsu K
J Immunol; 1984 Aug; 133(2):629-35. PubMed ID: 6234353
[TBL] [Abstract][Full Text] [Related]
17. V delta 5+ T cells of BALB/c mice recognize the murine heat shock protein 60 target cell specificity.
Kobayashi N; Matsuzaki G; Yoshikai Y; Seki R; Ivanyi J; Nomoto K
Immunology; 1994 Feb; 81(2):240-6. PubMed ID: 7908891
[TBL] [Abstract][Full Text] [Related]
18. Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo.
Frey AB
J Immunol; 1995 May; 154(9):4613-22. PubMed ID: 7722313
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of class II MHC antigen-restricted cloned autoreactive T cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer.
Shiohara T; Moellmann G; Jacobson K; Kuklinska E; Ruddle NH; Lerner AB
J Immunol; 1987 Mar; 138(6):1979-86. PubMed ID: 3493292
[TBL] [Abstract][Full Text] [Related]
20. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response.
Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F
Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
